Characteristics and Quality of Life in Patients with Chemotherapy-Induced Peripheral Neuropathy

항암화학요법으로 인한 암환자의 말초신경병증 관련 특성과 삶의 질

  • Kwak, Mi-Kyong (Department of Nursing, Samsung Medical Center) ;
  • Kim, Eun-Ji (Department of Nursing, Samsung Medical Center) ;
  • Lee, Eun-Ryung (Department of Nursing, Samsung Medical Center) ;
  • Kwon, In-Gak (Department of Clinical Nursing Science, Sunkyunkwan University School of Medicine) ;
  • Hwang, Moon-Sook (Department of Clinical Nursing Science, Sunkyunkwan University School of Medicine)
  • 곽미경 (삼성서울병원 간호부) ;
  • 김은지 (삼성서울병원 간호부) ;
  • 이은령 (삼성서울병원 간호부) ;
  • 권인각 (성균관대학교 의과대학 삼성서울병원 임상간호학교실) ;
  • 황문숙 (성균관대학교 의과대학 삼성서울병원 임상간호학교실)
  • Received : 2010.06.25
  • Accepted : 2010.08.02
  • Published : 2010.08.31


Purpose: The purpose of study was to identify how patients experienced chemotherapy-induced peripheral neuropathy (CIPN) and quality of life related to CIPN. Methods: This was a descriptive research. We collected data from 105 patients with chemotherapy-induced peripheral neuropathy. They completed a self-reported questionnaire including Eastern Cooperative Oncology Group (EORTC) CIPN20 and items related to their disease and peripheral neuropathy. The investigators filled in part of items about disease and treatment. Results: In the study, duration of peripheral neuropathy was 9.4 month and 54.3% of patients used pharmacological or non-pharmacological interventions. Patients reported the highest score for sensory scale and it's score was $38.74{\pm}20.24$. The scores for motor scale and autonomic scale were $21.95{\pm}19.19$ and $26.61{\pm}21.0$ respectively. This showed that patients more suffered from sensory neuropathy than any other domain of neuropathy. The most frequently selected two items were 'did you have tingling fingers or hands?' and 'did you have tingling toes or feet?'. Conclusion: The results of this study will provide useful information for chemotherapy-induced peripheral neuropathy.


  1. Wilkes GM. Neurologic disturbances. Cancer symptom management. Boston: Jones and Bartlett;1999.
  2. Ellen ML, Susan LB, Jeffrey C. The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum 2008;35:96-102.
  3. Sweeney CW. Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. Clin J Oncol Nurs 2002;6:163-6.
  4. Wilkes G. Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 2007;23:162-73.
  5. Wickhan R. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clin J Oncol Nurs 2007;11:361-76
  6. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care in Cancer, Online first at;2009.
  7. Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum 2005; 32:305-11.
  8. Boehmke MM & Dickerson SS. Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nurs 2005;28:382-9.
  9. Postma TJ, Heimans JJ. Grading of chemotherapy induced peripheral neuropathy. Annals of Oncology 2000;11:509-13.
  10. Katsumasa Kuroi, Kojiro Shimozuma, Yasuo Ohashi, Ayano Takeuchi, Toshihiko Aranishi, Satoshi Morita, et al. A questionnaire survey of physicians' perspective regarding the assessment of chemotheraphy-induced peripheral neuropathy in patients with Breast cancer. Jpn J Clin Oncol 2008;38:748-54.
  11. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41:1135-9.
  12. Campbell A. Subjective measures of well-being. Am Psychol 1976;31:117-24.
  13. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9-17.
  14. Smith EL, Whedon MK, Bookbinder M. Quality improvement of painful peripheral neuropathy. Semin Oncol Nurs 2002;18: 36-43.
  15. Backonja M, Beydoun A, Edwards KR. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280: 1831-6.
  16. Rao RD, Michalak JC, Sloan JA. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double blind, placebo-controlled, crossover trial. Cancer 2007;110:2110-8
  17. Kautio AL, Haanpaa M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2007;35:31-9.
  18. Balducci S, Lacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complicat 2006;20:216-23.
  19. Lindeman E, Leffers P, Spaans F, Drukker J, Reulen J, Kerckhoffs M, et al. Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: A randomized clinical trial. Arch Phys Med Rehabil 1995;76:612-20.
  20. Richardson J, Sandman D, Vela S. A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Arch Phys Med Rehabil 2001;82:205-9.
  21. Diana Donavan. Management of peripheral neuropathy caused by microtubule inhibitor. Clin J Oncol Nurs 2009;13:686-94.
  22. Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 2006; 10:279-87.
  23. Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M et al. NCCN task force report: Management of neuropathy in cancer. J Natl Compr Canc Netw 2009;7:S1-S26.
  24. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J the Peripher Nerv Syst 2008;13:27-46.